NY-AQARA
13.9.2022 09:01:43 CEST | Business Wire | Press release
Aqara, a leading provider of smart home products, introduced its Radiator Thermostat E1 to automate hydronic radiators including wall-mounted radiators, towel warmers and even warm floors, making the heating systems smarter for improved energy efficiency and comfort. This radiator thermostat supports most radiator valves with its M30*1.5mm thread connection and the provided adapters for RA, RAV and RAVL valves1. The Aqara Radiator Thermostat E1 is now available on European Amazon stores (France, Germany, Italy, Spain, UK), as well as via selective Aqara retailers in Europe2.
Based on the Zigbee 3.0 protocol, the Thermostat is expected to support the future-proofing Matter standard via an OTA update of the compatible, Zigbee 3.0-based Aqara hub3. The device is also compatible with major ecosystems and voice assistants such as HomeKit/Siri, Alexa, Google Home/Google Assistant, IFTTT, Home Assistant4 and more. Users can be reassured that the Thermostat works with their smart home setups of today and tomorrow.
Unlike many thermostatic radiator valves (TRVs) that rely solely on an internal sensor to measure the room temperature, which can be inaccurate due to the sensor’s proximity to the radiator, the Radiator Thermostat E1 can receive the temperature readings directly from a connected Aqara temperature sensor5 (including in HomeKit), and regulate the radiator based on the actual room temperature to increase comfort. Moreover, when connected to an Aqara Door and Window Sensor, the Thermostat can be configured to stop heating the room when any door or window is left open, in order to reduce energy waste. With the wide range of Aqara devices, users are able to create customized home automation that heats their homes only when it’s needed.
The Aqara Home app also offers various options for radiator automation. A smart schedule can be configured, allowing users to set the desired temperatures for different periods of time throughout the day, for example to set it to 5℃ during the daytime of weekdays when no one is at home, 25℃ for a relaxing evening after work, and 20℃ for a night of comfortable sleep. Geofencing is also possible, so the radiators will heat up the home before the family arrives. Another option is to automate the radiators based on local weather, and the heating will turn on automatically when the local temperature drops below a certain threshold.
Other features of the Radiator Thermostat include:
- Device grouping: multiple radiators in one room can be synchronized so that they work in a more efficient way, and make it possible to set different temperatures for each room;
- Multi-home management: in the case of having more than one home, users are able to manage the radiators in each home separately and set up individual automation such as geofencing-based automation;
- Anti-freeze mode: users can preset a temperature between 5℃ - 15℃ for this mode, and activate the mode easily when they are out of town to conserve energy while reducing the risk of pipe freezing;
- 12-month battery life: thanks to the Zigbee protocol and the energy-efficient hardware, 2 AA batteries will power the Thermostat for up to one year of use6.
To celebrate the launch, Aqara now offers a 10% discount for the Radiator Thermostat on its European Amazon stores in France, Germany, Italy, Spain and the UK with the promo code TRVE1UKEU. The code will be valid through September 15, 2022.
For more details of the Radiator Thermostat E1, please visit our website.
- This thermostat is only compatible with thermostatic valves, while manual, return temperature limiter (RTL) as well as monotube radiator systems are not supported. However in the majority of cases, it is possible to convert the existing radiator valve to a supporting one using an aftermarket adapter. Please consult professional installers or authorized Aqara retailers for more details.
- Product availability may vary among different retail channels, and could be updated all the time. It’s recommended to check with the local retailer(s) for real time availability.
- Matter support may be unavailable by the time of the launch.
- Home Assistant support can be achieved using HomeKit Controller integration, which is developed by the Home Assistant community.
- Aqara’s Temperature and Humidity Sensor or TVOC Air Quality Monitor is required.
- Battery life may vary depending on the usage. The 1-year battery life is calculated based on the assumption of 8 operations per day for a heating season of 165 days and 1 operation every 2 weeks for the rest 200 days.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220913005022/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LabPMM® Launches Global KMT2A MRD Testing Service to Support Menin Inhibitor Development and Acute Leukemia Care4.8.2026 09:10:00 CEST | Press release
LabPMM®, an Invivoscribe® subsidiary, today announced the global availability of its new KMT2A measurable residual disease (MRD) testing service. The highly sensitive digital PCR service is available to healthcare providers, clinical researchers, and biopharmaceutical partners through LabPMM’s global laboratory network, with CAP/CLIA-accredited testing available in the U.S. The service addresses a growing need for accurate molecular monitoring in acute leukemias.1,2,3 KMT2A rearrangements (KMT2Ar) are oncogenic drivers in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL).4 These rearrangements are present in about 80% of infant cases and 5-15% of childhood and adult leukemia cases.5 KMT2Ar leukemias are associated with chemotherapy resistance, high relapse rates, and poor clinical outcomes.5 The emergence of menin inhibitors is transforming the therapeutic landscape for patients with AML and ALL, particularly those with KMT2A-rearranged and NPM1-mutated disease.6 The
“HATSUNE MIKU LIGHTS TOKYO” Debuts on July 254.8.2026 09:00:00 CEST | Press release
Giant Hatsune Miku Returns to Light Up Tokyo’s Night! The Tokyo Metropolitan Government has been presenting year-round projection mapping displays on the Tokyo Metropolitan Government Building, using light and sound to showcase a wide range of artistic expressions as part of its efforts to create new nighttime tourism attractions in Tokyo. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260802298570/en/ © Crypton Future Media, INC. On Saturday, July 25, "HATSUNE MIKU LIGHTS TOKYO", featuring the globally beloved virtual singer Hatsune Miku, held its first screening. The work brings the world of the popular song “M@GICAL☆CURE! LOVE ♥ SHOT!” to life across the entire façade of the Tokyo Metropolitan Government Building. Since its launch in February 2024, “TOKYO Night & Light” has welcomed visitors from Japan and around the world, with total attendance surpassing 1.55 million. As one of Tokyo’s emerging landmark attractions, the
Mosaic Therapeutics appoints Dr Allison Jeynes as Chair of the Board4.8.2026 09:00:00 CEST | Press release
Accomplished life sciences leader with a proven track record of driving successful development of novel therapeutics, joins Mosaic to guide its next phase of growthAllison brings three decades of drug development, board and executive leadership experience to support Mosaic’s transition towards a clinical-stage company Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company developing novel, targeted drug combinations across a range of haematological and solid cancers, today announced the appointment of Dr Allison Jeynes as Chair of the Board to support its next phase of growth and advancement towards clinical development. Allison succeeds Dr Edward Hodgkin, who remains a Non-Executive Director of the Board. Allison is a UK-trained oncologist and highly-experienced life sciences leader, and brings over three decades of drug development and executive experience to Mosaic Therapeutics. As CEO of Avillion, a clinical development company, for the last 13 year
TOHKnet and Adtran conduct Japan’s first 50G PON trial on a live network4.8.2026 09:00:00 CEST | Press release
News summary: TOHKnet is exploring next-generation PON to meet enterprise demand while maintaining continuity across its regional fiber network Using Adtran technology, the trial validated 50G PON, XGS-PON and EPON operating together on a single fiber network Results show a practical path to evolve networks, enabling phased upgrades while maximizing fiber assets and avoiding service disruption Adtran today announced that TOHKnet has completed Japan’s first live network trial demonstrating the coexistence of 50G PON, XGS-PON and EPON on a single fiber. Conducted in Sendai using Adtran’s SDX 6400 Series OLT, the demo showed how the platform enables three generations of PON technology to operate together in a live service environment. The results highlight a realistic path for operators to introduce 50G PON capacity while maintaining continuity for existing services, maximizing the value of deployed fiber assets and reducing the complexity and disruption typically associated with network
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer4.8.2026 09:00:00 CEST | Press release
Study to evaluate rupitasertib, Evexta Bio’s first-in-class oral dual-node, S6K and AKT1/3 inhibitor in combination with giredestrant in second-line ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer; expected to initiate in Q4 2026First clinical collaboration and supply agreement for Evexta Bio with rupitasertib and for Roche with giredestrant; results to inform future strategy for rupitasertib combination in ER+ HER2- advanced /metastatic breast cancer Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration and supply agreement with plans to initiate a Phase 1b study combining its lead investigational compound, rupitasertib, with Roche’s investigational compound giredestrant, a selective estrogen receptor degrader (SERD), for the treatment of ER+, HER2-, ESR1-mutated advanced / metastatic breast cancer. Rupitasertib
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
